Literature DB >> 34604578

Should men be exempted from vaccination against human papillomavirus? Health disparities regarding HPV: the example of sexual minorities in Poland.

Konrad Reszka1, Łukasz Moskal1, Agata Remiorz1, Agata Walas1, Krzysztof Szewczyk2, Urszula Staszek-Szewczyk2,3.   

Abstract

INTRODUCTION: Social campaigns concerning vaccinations against human papillomavirus (HPV) in Poland are mainly addressed to women. In addition to cervical cancer, anal, penile, and oropharyngeal cancers can be caused by the virus, which clearly affects men as well. HPV vaccinations are voluntary and mostly not refunded in Poland.
METHODS: A survey was published on social media's group gathering males and contained questions concerning epidemiological data, knowledge about HPV, and opinions of HPV vaccination. A questionnaire was enriched with educational note regarding HPV-dependent cancers and available vaccines against HPV in Poland.
RESULTS: Because of age limitations, 169 males (115 heterosexuals, 48 homosexuals) aged 14-39 were chosen for the study. Seventyfive percent of straight and 88% of gay men were aware of HPV, but less than 4 and 17% (respectively) were vaccinated against the virus. Main sources of knowledge about HPV were the Internet (61%), media (28%) and relatives (27%). HPV infection was linked with the development of anal and oropharyngeal cancers by 28, and 37% of heterosexual males, compared with 56.3 and 43.8% of homosexual males. The majority of respondents (88%) indicated that all genders should be vaccinated, although only 57% were aware of HPV vaccination availability in Poland.
CONCLUSIONS: The men are at risk of HPV-related cancers and the danger is poorly understood amongst Polish men. Despite awareness of HPV vaccines, the vaccination rate is low. Consequently, there is a serious need to broaden educational campaignes with a special attention to LGBTQ+ communities. ©2021 Pacini Editore SRL, Pisa, Italy.

Entities:  

Keywords:  HPV; HPV vaccines; Health disparities; LGBTQ+; Underserved populations

Mesh:

Substances:

Year:  2021        PMID: 34604578      PMCID: PMC8451346          DOI: 10.15167/2421-4248/jpmh2021.62.2.1863

Source DB:  PubMed          Journal:  J Prev Med Hyg        ISSN: 1121-2233


Introduction

The incidence of sexually transmitted infections (STIs) in Poland is increasing, with human papillomavirus (HPV) the most common cause [1, 2]. HPV is a dsDNA virus, comprising more than 170 distinguishable types [3]. Almost every sexually active person is exposed to HPV during their lifetime and both women and men are at risk of infection. Approximately 90% of HPV infections are asymptomatic and resolve spontaneously [4]. However, in some cases infection results in palmar/plantar warts, laryngeal papillomatosis, precancerous lesions, and increased risk of developing cancer [2]. More than 99% of cervical cancer is associated with HPV infection (70% caused by HPV 16 and 18), constituting the sixth most common malignant neoplasm of reproductive organs among women and the seventh highest cause of cancer related death in Poland [3, 5]. Moreover, 70% of oropharyngeal, 63% of penile, and 91% of anal cancers are associated with HPV infection [5-7]. In some minority groups, such as gay men, the risk of HPV-dependent cancers is higher [8]. HPV can be transmitted through sexual intercourse, direct skin-to-skin contact, via contaminated surfaces, as well as during labour and the perinatal period (vertically) [2, 9]. The role of blood transfusions in the process of transmission remains uncertain [10]. Early sexual activity, multiple sexual partners or impaired immune function (e.g. immunosuppression) are the leading risk factors for HPV infection [4]. The Centres for Disease Control and Prevention (CDC) recommends mutually monogamous sexual relationships, barrier contraceptives, and vaccines as preventive masseurs [4, 11, 12]. The World Health Organization (WHO) states that vaccination against HPV is most effective prior to the onset of sexual activity [13]. In Poland HPV vaccinations are targeted at children aged 11-12, are voluntary and mostly not refunded [14]. Whilst the risk of developing HPV-dependant cancer applies to both men and women, social campaigns regarding vaccination against papillomavirus in Poland are aimed mainly at women. Due to a lack of sexual education in Polish schools, knowledge about STIs is usually obtained from the Internet, media, and social campaigns [15]. An absence of educational programs considering the health needs of LGBTQ+ communities in medical school curricula affects sexual minorities and results in health disparities [16, 17]. Studies regarding knowledge about HPV and vaccination rate among males in Poland are limited and to the best of our knowledge, there are no studies referring to sexual minorities in Poland. Therefore, we set out to explore the knowledge of Polish men about HPV infection and HPV-related cancers, and to identify any inequalities between heterosexual and homosexual men.

Methods

Institutional Review Board (IRB) approval was obtained from the Wroclaw Medical University. A survey comprising open-ended, close-ended, and nominal, multiple-choice questions with predefined answers was prepared in Google™ Form. For nominal questions an additional, optional space was provided for respondents to implement answers not included by authors. A non-probabilistic method of self-selection sampling was used for this study. Participation invitations were posted at selected groups on social media platforms such as Facebook™, Reddit™, and Wykop™. Target groups were found with the combinations of search terms: ‘men’, ‘boy’, ‘lad’, ‘Poland’, ‘polish’, ‘lgbt’, ‘lgbtqia’, and ‘lgbt+’. The inclusion criteria for group consisted of polish language, number of group’s male members above 25, number of posts above 20 while exclusion criteria included presence of homophobic content or hate speech and last post older than 2 weeks. Finally, survey was published on 32 groups. The questionnaire consisted of 20 questions divided into three parts. The first one concerned epidemiological profile of respondents: age, place of residence (metropolitan, non-metropolitan, rural), educational status (primary, secondary, professional, higher), medical education (medical/non-medical), and sexual orientation (straight, gay, other or I prefer not to say). The second part tested their knowledge about human papillomavirus, HPV-related diseases with distant implications of infection, possible routes of transmission, and prevention methods. The last part referred to vaccines as a protective tool against infection and opinions about HPV vaccines in Poland. Respondents were also asked to declare their vaccination status. At the end of the survey, the information note was projected on respondent’s screen with basic information about HPV related cancers and available vaccines in Poland. Moreover, a link to the educational page of the National Institute of Public Health concerning vaccinations against HPV was provided. Chi-square (χ2) independence test with Yates correction when necessary and Fisher exact test were used to assess the relationship between the studied variables in the nominal and ordinal scales. Shapiro-Wilk test was used to assess the normality of variable distribution. Mann-Whitney test was used to assess differences between heterosexual and homosexual males. Statistical analysis was performed using Statistica™ v.13.5 (StatSoft™).

Results

Six hundred seventy-one men were asked to participate in the study, 247 responded. Fifty-three participants were excluded due to incorrectly completed survey. In order to keep age distribution normal, age limit was established and outliers (25 respondents) were removed. Finally, 169 males (aged 14-39) were chosen for the study. The mean age of respondents is 22.7 (+/- 5 years). Most respondents were straight (68.05%), lived in large cities (35.50%), were educated to a secondary school level (53.85), were not medically trained (74.65%), and were not vaccinated against HPV (92.09%) (Tab. I).
Tab. I.

Characteristic of the study group.

VariableHeterosexual malesHomosexual malesTotal
Median age- yr. 22.523.122.7
Place of living – no. of citizens (%) City > 500.000 39 (33.91%)19 (39.58%)60 (35.50%)
City < 500.000 25 (21.74%)11 (22.92%)38 (22.49%)
City < 100.000 20 (17.39%)10 (20.83%)32 (18.93%)
City < 10.000 4 (3.48%)4 (8.33%)8 (4.73%)
Village 27 (23.48%)4 (8.33%)31 (18.34%)
Education level - no. (%) Primary 9 (7.83)8 (16.67%)19 (11.24%)
Secondary 68 (59.13%)21 (43.75%)91 (53.85%)
Higher 35 (30.43%)16 (33.33%)53 (31.36%)
Professional 3 (2.61%)3 (6.25%)6 (3.55%)
Medical education – no. (%) 33(28.70%)9 (18.75%)43 (25.44%)
Vaccinated individual against HPV – no. (%) 4 (3.48%)8 (16.67%)12 (7.10%)
The majority (78.7%) of participants were aware (e.g. had heard of the virus) of HPV. Sexually active males were more aware than those who were not sexually active (75.18 vs 24.82%, p < 0.05). Unsurprisingly, all participants with a medical education were aware of HPV. Participants living in cities with more than 100,000 habitants were more aware of HPV than those living in areas with less than 100,000 habitants (85.7 vs 69%, p < 0.05). However, population density is not correlated with greater general knowledge about the virus (p > 0.05). Whereas, place of residence influences on whether the concept of the virus is known, the percent of correct answers does not vary significantly between respondents from cities above 100,000 habitants and respondents from towns with less than 100,000 habitants and villages. The mean result in the first group is 61.6% of correct answers and 56.2% in second group (p > 0.05). The educational level is not associated with better outcomes either. The mean result of men with higher education level constitutes 61.7% of correct answers in comparison with men without higher education whose mean result is 58% (p > 0.05). Respondents reported that information about HPV was obtained most often from the Internet (60.94%), broadcast media (28.4%), and literature [newspapers, magazines, popular science books, and school manuals (24.26%)]. Other sources of knowledge included family/friends (23.67%), social campaigns (22.49%), physicians (21.89%), universities (8.18%), and schools (5.33%). Statistically better results (defined as more than 50% of correct answers) was observed in respondents whose reported the Internet, media, family/friends, physicians, literature, and universities as their sources of information about HPV (p < 0.05). Two-thirds of participants (62.72%) identified HPV infection as being associated with cervical cancer and 36.69% associated HPV with anal cancer. Vaginal and vulvar cancers were also considered a HPV-related diseases by 49.7% of participants, as was oropharyngeal cancer (38.46%), and plantar, and genital warts (43.2%). Most participants (81.07%) identified both sex intercourse, 42.6% identified labour and the perinatal period, 31.36% indicated skin-to-skin contacts, and 26.63% indicated contaminated surfaces. Two-thirds (62.13%) pointed out infected human blood and 14.79% considered droplets as a route of transmission. A small proportion thought that HPV can spread through contaminated food (9.74%) and insect bites (8.28%). Participants considered vaccination (81.66%), avoidance of sexual encounters (65.09%), and use of condoms (62.72%) as protective measure against HPV infection. Almost half (46.75%) indicated risk of HPV infection can be minimized by mutually monogamous relationships, while 44.37% indicated sexual abstinence. A healthy lifestyle (17.75%), the use of lubricant, and spermicides (42.6%), avoidance of crowded places (11.83%), prophylactic use of antibiotics/antiretroviral therapy (6.51%), elimination of contaminated food/water (5.36%), and use of repellents/insecticides (3.55%) were all proposed as means through which risk of HPV infection could be minimised. The vast majority of respondents (88.17%) know that both sexes should be vaccinated and 84.02% believe that vaccination should be compulsory in Poland. Conversely, 5.33% opposed mandatory immunization. More than half were aware of vaccine availability in Poland (56.80%), although 67.46% do not know whether vaccination is refunded. Most participants (73.37%) correctly identified that vaccination should occur before the commencement of sexual activity. Less than one-in-ten (7.1%) of participants were vaccinated against HPV. There are no statistically significant differences in vaccination rate between groups declaring medical education and non-medical education (9.30% versus 6.35%). Similarly, no links were demonstrated between residence and education level and uptake of vaccination among participants. No significant difference existed with regards to awareness of HPV between straight and gay participants (75.65 vs 87.5%). Homosexual participants indicated HPV infections increased the risk of anal cancer more frequently than heterosexual participants (43.75 vs 27.83%, p < 0.05). (Tab. II). Gay people were more frequently vaccinated against HPV than straight ones (16.67 vs 3.48%, p < 0.05).
Tab. II.

HPV-related diseases in opinion of respondents.

VariableHeterosexual malesHomosexual malesP-value
Diseases - no. of respondents (%) Cervical cancer 70 (60.87%)32 (66.67%)0.49
Anal cancer 32 (27.83%)27 (56.25%)< 0.001
Testicular cancer 28 (24.35%)16 (33.33%)0.93
Vaginal and vulvar cancers 55 (47.83%)26 (54.17%)0.46
Breast cancer 8 (6.96%)5 (10.42%)0.37
Colon cancer 12 (10.43%)10 (20.83%)0.77
Oropharyngeal cancer 42 (36.52%)21 (43.75%)0.39
Pancreatic cancer 5 (4.35%)4 (8.33%)0.45
Lung cancer 4 (3.48%)2 (4.17%)0.97
Plantar and palmar warts 50 (43.48%)22 (45.83%)0.78

Discussion

There are currently three vaccines available against HPV – bivalent, quadrivalent and nonavalent. Countries with national programs of vaccination (at least 10 years long) have noted a 90% reduction in HPV 6, 11, 16, 18 infections, 90% depletion in genital warts and 85% decrease in high grade squamous intraepithelial lesion (HSIL) of the uterine cervix [18]. A combined analysis of vaccination with bivalent vaccine unveiled that the vaccine was effective at preventing oral, anal, and cervical infections in the cohort of HPV naive women in 83.5% [19]. Data of vaccination effectiveness in occurrence of anal, penile, and oropharyngeal cancers is limited due to their low prevalence [20]. However, evidence is emerging that vaccination for males is warranted. In a study evaluating efficiency of quadrivalent HPV vaccine in men and boys, there was an overall 85.6% reduction in persistent infection of HPV 6, 11, 16, and 18, constituting preventive measure against anogenital cancer, intraepithelial neoplasia, recurrent respiratory papillomatosis and cancer of oropharynx [21]. Most programs target girls exclusively, with only a handful of countries (e.g. Australia, Austria, Canada) vaccinating both sexes [22]. A systematic review and meta-analysis of predictions from transmission-dynamic models funded by Canadian Institutes of Health Research suggest that elimination of HPV 6, 11, 16, and 18 is possible when 80% coverage in girls and boys is reached and a high vaccine efficacy is maintained over time [22]. In 2007, Australia introduced a national HPV vaccination program, which was broadened in 2013 by vaccination of both sexes. In 2017 Australia achieved vaccination levels of 80.2% in girls and 75.9% in boys at the age of 15. It is estimated that the age-standardised annual incidence of cervical cancer will decrease to less than 4 new cases per 100,000 women by 2028 [23]. There are no specific analyses concerning the coverage vaccination level against HPV in Poland. According to estimates of Major Statistical Department, the vaccination level in Poland fluctuates around 7.5-10% [24]. However, it is estimated that vaccination for boys is much lower. In Poland, the vaccine is not mandatory, but recommended by the Ministry of Health [14]. The total cost of vaccination (regardless of type) for one child in Poland is 246 USD [25]. In 2018 the average expenditure per capita in Polish household was 286,65 USD [26]. Consequently, the cost of vaccination in Poland for one person is almost the equivalent of one month’s maintenance. Currently in Poland, numerous reimbursement programs for vaccination are being implemented by local governments and are located in the southern/western parts of the country. Only 12 municipalities organize vaccinations for girls and boys [27]. This situation varies from year to year, depending on how the funds are allocated. This is likely to account for the variability in responses in regarding vaccinations reimbursement among the participants. Current WHO recommendations target primary HPV vaccination to the population of girls aged 9-14, prior to becoming sexually active, with at least 2-dose schedule. WHO suggests that achieving > 80% vaccination coverage in girls also reduces the risk of HPV infection for boys due to herd protection. Vaccination regardless of gender and age should be considered with other elements, such as competing health priorities, disease burden, programmatic implications, cost-effectiveness, and affordability [28]. The Advisory Committee on Immunization Practices (ACIP) endorses vaccination of all boys and girls under age of 11 or 12 [12]. Catch-up vaccines are recommended for males through age 21 and 26 for females. Furthermore, the CDC advocates vaccination for homosexual men and for both men and women with compromised immune systems, by the age of 26 if they were not fully vaccinated previously [12]. Thus, the need for vaccination among boys and adult men, especially those from higher risk groups cannot be omitted [29].

LIMITATIONS

As the self-selection sampling option was chosen for, there is no random sample. Consequently, the study group may not be representative of the entire population. Taking under consideration the low number of participants (169 males), the study group should be extended in further research. Any identification verification tool was used in the study, thus one person can submit multiple responses. What is more, the fact that gay men could identify themselves as straight in the survey cannot be forgotten.

Conclusions

The men are at risk of HPV-related cancers and the danger is poorly understood amongst Polish men. Whilst the WHO suggests that vaccination rates of 80% of girls will protect men through heard immunity, gay men remain at risk. As such, HPV vaccination programs need to be extended to include boys and made more affordable to increase uptake for both sexes. Our study has demonstrated that knowledge about HPV is no correlated with place of residence and level of education. Educational campaigns have demonstrated minimal effectiveness, suggesting that funds should be transferred to improving their influence or expanding training programs within schools and universities. Further, surcharging of HPV vaccines should be introduced. The introduction of compulsory, refunded vaccines is likely the most effective means through which to increase the percentage of vaccinated people, thus decreasing the number of HPV-related cancers in Poland. Few respondents indicated doctors as a potential source of information about HPV. This situation requires greater engagement of physicians in programs referring to education and prophylaxis. We urge medical schools to broaden the knowledge of Polish medical students and healthcare professionals about health needs of LGBTQ+ communities, preventing from health disparities in the future. Characteristic of the study group. HPV-related diseases in opinion of respondents.
  16 in total

1.  HPV-beyond cervical cancer (online resource center).

Authors:  Kenneth A Alexander; Anna R Giuliano
Journal:  Am J Med       Date:  2012-07       Impact factor: 4.965

2.  US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.

Authors:  Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman
Journal:  J Natl Cancer Inst       Date:  2015-04-29       Impact factor: 13.506

3.  Human Papillomavirus (HPV) Infections and the Importance of HPV Vaccination.

Authors:  Chia-Ching J Wang; Joel M Palefsky
Journal:  Curr Epidemiol Rep       Date:  2015-03-26

Review 4.  HPV vaccination and the effects on rates of HPV-related cancers.

Authors:  Jessica St Laurent; Rebecca Luckett; Sarah Feldman
Journal:  Curr Probl Cancer       Date:  2018-06-23       Impact factor: 3.187

5.  The projected timeframe until cervical cancer elimination in Australia: a modelling study.

Authors:  Michaela T Hall; Kate T Simms; Jie-Bin Lew; Megan A Smith; Julia Ml Brotherton; Marion Saville; Ian H Frazer; Karen Canfell
Journal:  Lancet Public Health       Date:  2018-10-02

6.  Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations.

Authors: 
Journal:  Vaccine       Date:  2017-06-05       Impact factor: 3.641

7.  Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.

Authors:  Tim Palmer; Lynn Wallace; Kevin G Pollock; Kate Cuschieri; Chris Robertson; Kim Kavanagh; Margaret Cruickshank
Journal:  BMJ       Date:  2019-04-03

8.  Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices.

Authors:  Elissa Meites; Peter G Szilagyi; Harrell W Chesson; Elizabeth R Unger; José R Romero; Lauri E Markowitz
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-08-16       Impact factor: 17.586

9.  Risk of vertical transmission of human papillomavirus throughout pregnancy: a prospective study.

Authors:  Seung Mi Lee; Joong Shin Park; Errol R Norwitz; Ja Nam Koo; Ig Hwan Oh; Jeong Woo Park; Sun Min Kim; Yun Hwan Kim; Chan-Wook Park; Yong Sang Song
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

10.  Economic barriers, evidentiary gaps, and ethical conundrums: a qualitative study of physicians' challenges recommending HPV vaccination to older gay, bisexual, and other men who have sex with men.

Authors:  Daniel Grace; Mark Gaspar; Ron Rosenes; Ramandip Grewal; Ann N Burchell; Troy Grennan; Irving E Salit
Journal:  Int J Equity Health       Date:  2019-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.